Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results

FDA Feedback Supports Planned Emergency Use Authorization (EUA) Submission for ADG20 for Prevention of COVID–19; Interim Clinical Data Package from EVADE Prevention Trial to Support EUA Submission Expected in Second Quarter 2022

Enrollment Progressing in ADG20 STAMP Trial for Treatment of COVID–19; Planned Interim Efficacy Analysis Expected in Second Quarter 2022 to Support Potential EUA Submission

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical–stage biopharmaceutical company focused on the discovery, development and commercialization of antibody–based solutions for infectious diseases with pandemic potential, today provided an update on its lead COVID–19 antibody program, ADG20, and reported third quarter 2021 financial results. ADG20 is an investigational monoclonal antibody product candidate designed to provide broad and potent neutralizing activity against SARS–CoV–2, including variants of concern, for the prevention and treatment of COVID–19.

"ADG20 continues to be the only monoclonal antibody in late–stage development that has the potential to offer a unique combination of potency, breadth of neutralization across known SARS–CoV–2 variants of concern as well as additional SARS–like viruses with pandemic potential, and durable protection against COVID–19 for up to one year. Further, our single injection delivery avoids the inconveniences associated with IV administration or multiple injections," said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. "The world continues to face a host of challenges in fully addressing the COVID–19 crisis. Alternatives or supplements to vaccines for the prevention of COVID–19 are needed for immunocompromised individuals and those who remain hesitant to receive a vaccine or to vaccinate their children. Certain patient populations may not be ideal candidates for emerging oral treatment options due to adherence concerns, comorbidities or possible drug interactions. Based on its combined attributes, ADG20 has the potential to be a differentiated alternative for the prevention and treatment of COVID–19 that may address the needs of these populations, and our commitment to its advancement is unwavering."

"We've made significant progress over the course of 2021, and 2022 is set to be a landmark year for Adagio as we prepare for potential EUA submissions for ADG20 for the prevention and treatment of COVID–19," said Tillman Gerngross, Ph.D., co–founder and chief executive officer of Adagio. "We recently received clear feedback from the FDA on a strategy to submit an EUA for ADG20 for the prevention of COVID–19, and have initiated efforts to expand our clinical program to additional patient subsets, including immunocompromised individuals and children. Our commercial–readiness efforts are well underway and with a strong balance sheet, we are ready to move quickly to enable access to individuals in need of COVID–19 prevention and treatment options, if authorization and/or approval is granted."

ADG20 COVID–19 Program Updates

Prevention
Adagio continues to enroll adult and adolescent participants in its ongoing, global Phase 3 EVADE clinical trial evaluating ADG20 as a prevention for COVID–19 in both the pre–exposure and recent exposure settings.

  • Adagio has received feedback from the U.S. Food and Drug Administration (FDA) on a data package needed and a pathway for an EUA submission for the pre–exposure prevention of COVID–19
  • Adagio anticipates that the data package to support an EUA for ADG20 will be available in the second quarter of 2022 followed by expected submission to the FDA in the third quarter of 2022
  • Adagio plans to add a new cohort in EVADE to evaluate ADG20 as a preventative option in immunocompromised individuals, with enrollment expected to begin in the first quarter of 2022
  • Adagio also plans to initiate a trial evaluating ADG20 as a vaccine supplement
  • Following discussion with the FDA, Adagio has aligned on a plan to evaluate ADG20 as a preventative option in the pediatric population, with a trial in individuals between two and 11 years of age expected to be initiated by mid–year 2022

Treatment
Adagio continues to enroll patients in its ongoing, global Phase 2/3 STAMP clinical trial evaluating ADG20 as a treatment for COVID–19.

  • Adagio is planning to modify the trial design in order to expand the at–risk patient population eligible for enrollment in STAMP
  • Based on current enrollment, Adagio anticipates reaching the Phase 2 independent data monitoring committee evaluation in the first quarter of 2022 and the interim efficacy analysis in the second quarter of 2022 to potentially support a subsequent EUA submission

Recent ADG20 Data Presentations at ISIRV–WHO and IDWeek2021

  • New in vitro data demonstrated retained neutralizing activity of ADG20 against a diverse panel of circulating SARS–CoV–2 variants, including the newly emerged Lambda, Mu and Delta plus variants. Notably, findings showed that ADG20 demonstrated potent neutralizing activity against all SARS–CoV–2 variants of concern tested, including those with reduced susceptibility to mAb products currently available under EUA or in late–stage development.
  • Data from a six–month evaluation in Adagio's Phase 1 healthy volunteer trial of ADG20 confirmed the extended half–life of ADG20, which approached 100 days based on data from the 300 mg intramuscular dose that was given as a single injection. In addition, an exploratory analysis showed that 50% serum virus neutralization titers at six months after a 300 mg intramuscular dose of ADG20 were similar to observed peak titers with the mRNA–1273 vaccine and exceeded those achieved with the AZD1222 vaccine series. ADG20 was well–tolerated with no study drug–related adverse events (AEs), serious AEs, or injection–site or hypersensitivity reactions reported through a minimum of three months follow–up across all cohorts.
  • To support dose selection for Adagio's global Phase 2/3 STAMP and EVADE clinical trials, the company modified an existing quantitative systems pharmacology whole–body physiologically–based pharmacokinetic (QSP/PBPK) model to better characterize the PK of extended half–life mAbs in serum and key sites of viral replication in the respiratory tract. Adagio's model adequately a priori predicted the observed ADG20 serum PK in non–human primates (NHPs) and humans. The model was further optimized based on data from Adagio's Phase 1 clinical trial and then applied for dose selection for STAMP and EVADE, ultimately informing selection of the 300 mg intramuscular dose for the trials.

Intellectual Property

On October 29, 2021, the United States Patent and Trademark Office mailed a notice of allowance to the company for a patent application that will provide patent protection for ADG20 in the U.S.

Third Quarter 2021 Financial Results

  • As of September 30, 2021, Adagio had cash, cash equivalents and marketable securities of $666.3 million, which are expected to support the company's current operating plans into 2023.
  • Research & development expenses including in–process research and development for the third quarter of 2021 were $49.4 million.
  • Selling, general & administrative expenses for the third quarter of 2021 were $11.1 million.
  • Net loss for the third quarter was $60.4 million, or $0.98 per share.

About ADG20
ADG20, an investigational monoclonal antibody targeting the spike protein of SARS–CoV–2 and related coronaviruses, is advancing through global clinical trials for the prevention and treatment of COVID–19, the disease caused by SARS–CoV–2. ADG20 was designed and engineered to possess high potency and broad neutralization activity against SARS–CoV–2 and additional clade 1 sarbecoviruses by targeting a highly conserved epitope in the receptor binding domain. ADG20 was further engineered to provide an extended half–life for durable protection. ADG20 has demonstrated potent neutralizing activity against the original SARS–CoV–2 virus, all known SARS–CoV–2 variants of concern and additional SARS–like viruses in preclinical studies. ADG20 is administered in clinical trials by a single intramuscular injection. To date, ADG20 has been well–tolerated in a Phase 1 trial with no safety signals identified through a minimum of three months follow–up across all cohorts. ADG20 has not been approved for use in any country, and safety and efficacy have not yet been established.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical–stage biopharmaceutical company focused on the discovery, development and commercialization of antibody–based solutions for infectious diseases with pandemic potential, including COVID–19 and influenza. The company's portfolio of antibodies has been optimized using Adimab's industry–leading antibody engineering capabilities and is designed to provide patients and clinicians with the potential for a powerful combination of potency, breadth, durable protection (via half–life extension), manufacturability and affordability. Adagio's portfolio of SARS–CoV–2 antibodies includes multiple non–competing, broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third–party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring the potential for broad accessibility to people around the world. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward–looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects," "intends," "projects," and "future" or similar expressions are intended to identify forward–looking statements. Forward–looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned EUA submissions, initiation, modification and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients, including in specific populations, with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our expectations regarding the scope of any approved indication for ADG20; and the benefits of our product candidates to patients; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward–looking statements and you should not place undue reliance on our forward–looking statements. These forward–looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward–looking statements, including, without limitation, the impacts of the COVID–19 pandemic on our business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and the uncertainties and timing of the regulatory approval process. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward–looking statements in this press release are described under the heading "Risk Factors" in Adagio's Quarterly Report on Form 10–Q for the quarter ended June 30, 2021 and in Adagio's future reports to be filed with the SEC, including Adagio's Quarterly Report on Form 10–Q for the quarter ended September 30, 2021. Such risks may be amplified by the impacts of the COVID–19 pandemic. Forward–looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com


ADAGIO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands, except share and per share amounts)

September 30,
2021
December 31,
2020
Assets
Current assets:
Cash and cash equivalents $ 478,269 $ 114,988
Marketable securities 188,053 ""
Prepaid expenses and other current assets 13,833 2,394
Total current assets 680,155 117,382
Other non–current assets 6,115 ""
Total assets $ 686,270 $ 117,382
Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)
Current liabilities:
Accounts payable $ 17,564 $ 8,153
Accrued expenses 35,485 4,919
Total current liabilities 53,049 13,072
Early–exercise liability 8 11
Total liabilities 53,057 13,083
Commitments and contingencies
Convertible preferred stock (Series A, B and C) $0.0001 par value; no shares authorized, issued and outstanding at September 30, 2021; 12,647,934 shares authorized, issued and outstanding at December 31, 2020; aggregate liquidation preference of $0 and $169,900 at September 30, 2021 and December 31, 2020, respectively "" 169,548
Stockholders' equity (deficit):
Preferred stock:
Undesignated preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2021; no shares authorized at December 31, 2020; no shares issued and outstanding at September 30, 2021 and December 31, 2020 "" ""
Common stock, $0.0001 par value; 1,000,000,000 shares authorized at September 30, 2021; 150,000,000 shares authorized at December 31, 2020; 111,251,660 shares issued and outstanding at September 30, 2021; 28,193,240 shares issued and 5,593,240 shares outstanding at December 31, 2020 5 1
Treasury stock, at cost; no shares and 22,600,000 shares at September 30, 2021 and December 31, 2020, respectively "" (85 )
Additional paid–in capital 842,272 154
Accumulated other comprehensive income 3 ""
Accumulated deficit (209,067 ) (65,319 )
Total stockholders' equity (deficit) 633,213 (65,249 )
Total liabilities, convertible preferred stock and stockholders' equity (deficit) $ 686,270 $ 117,382


ADAGIO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(In thousands, except share and per share amounts)

Three Months
Ended
September 30,
Three Months
Ended
September 30,
Nine Months
Ended
September 30,
Period from
June 3, 2020
(Inception) to
September 30,
2021 2020 2021 2020
Operating expenses:
Research and development(1) $ 45,366 $ 7,251 $ 114,465 $ 7,299
Acquired in–process research and development(2) 4,000 39,915 7,500 39,915
Selling, general and administrative 11,052 842 21,853 892
Total operating expenses 60,418 48,008 143,818 48,106
Loss from operations (60,418 ) (48,008 ) (143,818 ) (48,106 )
Other income (expense):
Interest income 48 "" 80 ""
Other expense (5 ) "" (10 ) ""
Total other income (expense), net 43 "" 70 ""
Net loss (60,375 ) (48,008 ) (143,748 ) (48,106 )
Other comprehensive income (loss)
Unrealized gain on available–for–sale securities, net of tax 3 "" 3 ""
Comprehensive loss $ (60,372 ) $ (48,008 ) $ (143,745 ) $ (48,106 )
Net loss per share attributable to common stockholders, basic and diluted $ (0.98 ) $ (25.98 ) $ (7.06 ) $ (7.55 )
Weighted–average common shares outstanding, basic and diluted 61,297,086 1,847,826 20,346,771 6,375,000

(1) Includes related–party amounts of $1,826 and $2,261 for the three and nine months ended September 30, 2021, respectively, and $291 for both the three months ended September 30, 2020 and for the period from June 3, 2020 (inception) to September 30, 2020.
(2) Includes related–party amounts of $4,000 and $7,500 for the three and nine months ended September 30, 2021, respectively, and $39,915 for both the three months ended September 30, 2020 and for the period from June 3, 2020 (inception) to September 30, 2020.


Growing Digital Divide Threatens Recovery from Covid-19

Credit: EBRD

• EBRD Transition Report 2021-22 highlights growing gaps in the use of online services and digital skills since the start of the Covid-19 pandemic
• Investment returns on digital services are far higher in economies with greater digital skills
• A “brain drain” of digitally skilled workers is affecting some countries’ prospects

By Richard Porter
LONDON, Nov 15 2021 – A growing digital divide is emerging as a major threat to a robust recovery from the Covid-19 pandemic, according to new research by the European Bank for Reconstruction and Development (EBRD).

The Bank’s Transition Report 2021-22 ‒ System Upgrade: Delivering the Digital Dividend reveals the increasing gap between economies that have stepped up their use of online and digital services and those that have fallen further behind.

The report focuses on the 38 economies in which the EBRD invests. The Bank found that, since the start of the pandemic, people who are wealthier, living in cities and more advanced economies are better able to order goods and services online, do their banking through the internet and work from home.

Elsewhere, large parts of the population remain excluded from these opportunities and are more at risk of losing their jobs as digital technology becomes more widely used. Furthermore, many economies in the EBRD regions are experiencing significant “brain drain”, as people with strong digital skills move abroad.

While highlighting the digital divide, the report also shows how much progress has been made on the provision and use of digital and online services since the start of the Covid-19 crisis.

EBRD Chief Economist Beata Javorcik said: “In many countries, large parts of the economy, as well as schools and universities, went online in a matter of days when the Covid-19 pandemic hit. The digitalisation process is destined to continue and will remain one of the key forces shaping our world. Yet there are large digital divides between the EBRD regions and the advanced economies, between the various economies in the EBRD regions and within individual economies. Addressing these divisions is vital to their success.”

Helping countries and clients with their transition to digital technology is one of three strategic priorities for the EBRD, along with tackling climate change and supporting economic inclusion.

The EBRD announced its new strategic approach on accelerating the digital transition setting out how it will use all the instruments at its disposal ‒ policy, investment and advisory activities ‒ to unleash the transformational power of digital technology in the economies where it invests.

A new index of digital transformation

The Transition Report 2021-22 introduces a new index of digital transformation as a way of assessing the divide between and within countries. In the economies where the EBRD operates, only Estonia scores in excess of the average of more developed economies. The index calculates a score based on 22 different measures of the availability and use of digital technologies.

Estonia’s index score of 92.2 is the highest in the EBRD regions. Turkmenistan’s is lowest, at 16.1, while Tajikistan’s is next, at 23.7. The quality of regulation and online access to government services is one of the main reasons for these low scores.

Among other EBRD investee economies, Egypt, Tunisia and Morocco post low scores for digital skills, while Lithuania and Slovenia come in higher, alongside Estonia.

The key constraint on digital development is insufficient skills. There is evidence that more educated people in the EBRD regions have been improving their digital skills, catching up with the most developed nations. However, older people and those with lower levels of education and income are increasingly being left behind.

This is having an increasing impact as digital technologies are used more widely in all industries. Occupations that are more exposed to automation through the use of artificial intelligence have seen more job losses. Workers with fewer digital skills find it harder to adapt to new roles that become available.

The report also looks at the effect on economies and on financial services of investing in digital technologies.

On investment, it finds that the returns on digital-intensive capital are significantly higher in economies with stronger digital skills. A case study looking at high-speed broadband in Turkey shows that firms with better connectivity are more likely to export and introduce new products.

In Russia, smaller firms have increased staff numbers by about 19 per cent, on average, following the roll-out of 4G mobile technology.

Access to financial services for households and small businesses has been improved by the growth of digital finance. However, at the same time, banks have been reducing the number of physical branches.

And while some alternative finance platforms have emerged, they have been primarily focussed on debt rather than equity funding – unlike some more developed markets.

Beata Javorcik said: “The future is digital, and our task is to deliver the digital dividend as quickly and smoothly as possible. I firmly believe that with the right kind of digital transition, the economies of the EBRD regions will enjoy increased prosperity, better social outcomes and greater environmental sustainability.”

Lack of trust and low levels of digital skill constrain remote working

Richard Porter is Director of Communications at the European Bank for Reconstruction and Development (EBRD)

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);